UDG shares have tripled over the past five years, but the best may be yet to come
The company has travelled a long road since its transition from United Drug
The ace cards that have delivered spectacular returns for UDG shareholders over the past five years have been the company’s high calibre and experienced acquisition team; its strategic and financially disciplined approach to choosing acquirees that have real sources of competitive advantage and pricing power and can be realistically targeted to deliver double-digit to mid-teen returns on capital employed, and management’s proven expertise in integration and innovation, as well as building business models ...
